Navigation Links
DyCE(TM) (Dynamic Contrast Enhancement) Technology Now Part of CRi's Analysis Software Suite for the Popular Maestro(TM) in vivo Molecular Imaging System
Date:3/20/2008

WOBURN, Mass., March 20 /PRNewswire/ -- Cambridge Research & Instrumentation, Inc. (CRi) is shipping DyCE(TM) (Dynamic Contrast Enhancement), a new technology application, to users of the award-winning Maestro(TM) in vivo molecular imaging system. Customers can now generate all- optical anatomical images of mouse models in only a few minutes, saving time and enabling better time-resolved images of molecular probe distribution.

CRi has an exclusive commercialization agreement with Massachusetts General Hospital (MGH) for its DyCE application which received widespread acclaim when introduced at the recent Society of Molecular Imaging/Academy of Molecular Imaging joint conference for in vivo imaging. DyCE was also featured in the cover article in Nature Photonics in August of 2007.

"DyCE is a quantum leap forward for optical imaging, poised to revolutionize in vivo fluorescence imaging," says James Mansfield, Director of Multispectral Imaging Systems at CRi. "Our customers can now produce anatomical images in record time and also save significant money versus conventional means."

Anatomical images are produced using DyCE in the following way. A bolus of an inert near-infrared dye (such as indocyanine green) is injected, and then a time-based series of data is collected. Using CRi's analysis software, this data set is interpreted to delineate most of the major organ systems, using optical imaging alone. This organ-specific imaging is possible, because organs have characteristic uptake or distribution patterns over time that can be 'illuminated' by the dye passing through, distinguishing them from other structures.

These in vivo anatomical maps can be overlaid co-registered with simultaneously acquired images of a targeted molecular probe to delineate the marker's specific anatomical and physical location at any time point in the study.

"CRi is uniquely positioned to commercialize DyCE capitalizing on the combination of our advan
'/>"/>

SOURCE Cambridge Research & Instrumentation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Parker Waichman Alonso LLP Files Suit Against General Electric Company on Behalf of a Man Who Developed Nephrogenic Systemic Fibrosis (NSF) from Contrast Agent Omniscan
2. Allergic reactions to gadolinium-based contrast agents are rare, study finds
3. Bayer HealthCare Pharmaceuticals and MedAssets Supply Chain Systems Sign a Three-Year Agreement for Magnevist(R) Magnetic Resonance Contrast Media
4. Stem Cell Technology Offers Promise of Huge Savings for Drug Developers
5. Genetic Engineering & Biotechnology News reports on clinical trials in developing countries
6. New England Technology Foundation Announces Connecting for Childrens Charities 2008 Event
7. Healthcare Tech and the World: Personalized Technology to Benefit Healthcare Consumers in the Future
8. RIVAs Cutting Edge Technology To Help Intermountain Healthcare Enhance Medication Delivery Safety
9. New Technology No Better at Spotting Anesthesia Awareness
10. Virtual reality and computer technology improve stroke rehabilitation
11. Advanced Technology in Dental Imaging Benefits Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...ELHI, India, Dec. 5 He...zation today launched a global partnership to subs...ccurate and affordable alternatives. , , Th...h Asian Conference on Alternatives to Mercury in H...tions and the Indian NGO Toxics Link. , , "...
(Date:12/4/2008)... CEO marks 10th anniversary of drive to eliminate ...lionth albendazole tablet and grant to The Carter ... In a meeting today with ...nter, Jimmy Carter, as well as global health thoug...(LSE/NYSE: GSK ) announced that it has made a $2...
(Date:12/4/2008)...UKEE, Dec. 4 Aurora Health Care is...amin D supplements. Aurora,s Care Management,Clin...o educate all Aurora,caregivers about the benefit...owing evidence that higher Vitamin D levels may im...steoporosis, certain muscle conditions and,season...
(Date:12/4/2008)...RBOR, Mich., Dec. 4 BAPTIST HEALTH...., and the state,s largest health system, has,exp... Thomson Reuters -- a,solution that enabled the s...,interventions and save more than $1 million. , ...tle Rock campus show that,CareFocus prompts appro...
Breaking Medicine News(10 mins):Health News:Health Care Without Harm, WHO Announce Partnership for Global Reduction of Mercury-Based Medical Devices 2Health News:GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program 2Health News:GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program 3Health News:GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program 4Health News:Aurora Health Care Urges All Wisconsin Residents to Take Vitamin D 2Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 2Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 3
...ssor of animal science and microbiology and molecu...te University found that a new cell// line has the...s is good news because it would result in the prod...s which is cheaper and produced in a shorter perio...
..., differences in the treatment given to male and f...ms persist, a new study has found//. In all, the ...nefit from hospitals' quality-improvement measures... the drugs, tests, and counseling about smoking, d...
...ns have succumbed to chikun gunya at Kandamanur vi... members of each family have been affected by the .../ Demanding that the government take immediate st..., vice chairperson of Mayuladumparai panchayat uni...
...g the tissue abnormalities, or lesions, that typic...men infected with multiple genotypes// of the huma...ccording to a study published in the July issue of...evention. Although doctors have known that the ce...
Other Medicine News:Health News:New Cell Lines Cuts Down the Cost and Time in the Production of Flu Vaccine 2Health News:Heart Attack Care Continues To Be Biased In Favor Of Men 2Health News:Heart Attack Care Continues To Be Biased In Favor Of Men 3Health News:Higher Risk for Cervical Cancer Seen Among Women Infected with Multiple HPV Types 2Health News:Higher Risk for Cervical Cancer Seen Among Women Infected with Multiple HPV Types 3
(Date:12/4/2008)... PARK, Calif., Dec. 4 Long-term da...expected decrease in Mitral Vale Area (MVA),after...tral regurgitation (MR),is not associated with cl...,with two years of follow-up, none of the patien...surgery for mitral stenosis. At 12 months no,impo...
(Date:12/3/2008)...igna front-line data demonstrating potential in ne...e of leukemia to be featured in two oral sessions ...benefits for chronically transfused patients by si...y organs , , - New long-term data from majo...rt on optimal post-surgery treatment strategy, Fem...
(Date:12/3/2008)...GEVILLE, Pa., Dec. 3 Wye...WYE ), announced today that it has submitted a,ma...opean Medicines Agency,(EMEA) for approval to mar...njugate vaccine (PCV13) for infants and young chil...vention of pneumococcal disease (PD) caused by the...
(Date:12/2/2008)...GO, Dec. 3 Researchers ...the circuitry in the area of the brain,responsibl...nts suffering from,stress-related psychiatric dis...day at the annual meeting of the Radiological Soci...ts with major depression and other stress-related ...
Breaking Medicine Technology:Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 2Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 3Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 2Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 3Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 4Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 5Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO 26 Investor Conference 2725 1Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO 26 Investor Conference 2725 2Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO 26 Investor Conference 2725 3Rochester Medical Announces First Quarter 2008 Earnings Conference Call February 4 2008 10053 1Rochester Medical Announces First Quarter 2008 Earnings Conference Call February 4 2008 10053 2Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2724 1Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2724 2Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2724 3Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2724 4Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 1Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 2Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 3Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 4Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 5Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 6
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
Medicine Products: